Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Decreases By 73.3%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 223,898 shares, a decline of 73.3% from the July 30th total of 839,994 shares. Based on an average daily trading volume, of 903,947 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.6% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC acquired a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Price Performance

Shares of MTNB remained flat at $0.20 on Friday. 386,117 shares of the company were exchanged, compared to its average volume of 1,469,259. The stock’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $0.54. Matinas Biopharma has a twelve month low of $0.18 and a twelve month high of $2.14. The stock has a market cap of $2.94 million, a PE ratio of -0.17 and a beta of 1.76.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.